ALT

3.06

1.32% 0.04

アフターアワーズ： 3.02 -0.04 -1.31%

Altimmune Inc (ALT)

概要ニュース株価時系列オプションチェーン Financials ディスカッション予測株式分割株の配当実績

前日終値:

$3.02

開ける：

$3.08

24時間の取引高:

3.46M

Relative Volume:

0.86

時価総額：

$594.73M

収益：

$41,000

当期純損益:

$-88.09M

株価収益率:

-3.0136

EPS:

-1.0154

ネットキャッシュフロー:

$-67.55M

1週間パフォーマンス:

+11.68%

1か月パフォーマンス:

-8.38%

6か月パフォーマンス:

-18.40%

1年パフォーマンス:

-43.65%

1日の値動き範囲:

$3.00

$3.15

1週間の範囲:

$2.56

$3.15

52週間の値動き範囲:

$2.56

$7.73

Altimmune Inc Stock (ALT) Company Profile

名前

Altimmune Inc

セクター

Healthcare (1106)

産業

Biotechnology (615)

電話

(240) 654-1450

住所

910 CLOPPER ROAD, GAITHERSBURG, MD

職員

Twitter

次回の収益日

2026-05-12

最新のSEC提出書

ALT's Discussions on Twitter

Compare ALT vs VRTX, REGN, ARGX, ALNY, ONC

株式	価格	時価総額	収益	当期純利益	現金流量	EPS
ALT Altimmune Inc	3.06	586.95M	41,000	-88.09M	-67.55M	-1.0154
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Altimmune Inc Stock (ALT) Upgrades & Downgrades

日付	アクション	アナリスト	評価の変更
2026-04-24	アップグレード	Goldman	Sell → Neutral
2026-03-18	開始されました	Truist	Buy
2026-01-28	開始されました	Barclays	Overweight
2025-07-10	再開されました	Goldman	Sell
2025-02-28	開始されました	William Blair	Mkt Perform
2025-01-08	開始されました	Stifel	Buy
2024-11-12	開始されました	UBS	Buy
2024-04-29	ダウングレード	Guggenheim	Buy → Neutral
2024-01-24	開始されました	Goldman	Neutral
2023-03-22	ダウングレード	Goldman	Buy → Neutral
2022-12-01	開始されました	Goldman	Buy
2021-12-29	再開されました	Jefferies	Buy
2021-06-02	開始されました	H.C. Wainwright	Buy
2021-02-11	開始されました	Guggenheim	Buy
2020-12-14	開始されました	Jefferies	Buy
2020-11-12	繰り返されました	B. Riley Securities	Buy
2020-09-25	開始されました	B. Riley FBR	Buy
2020-08-14	開始されました	Evercore ISI	Outperform
2020-07-31	開始されました	Piper Sandler	Overweight
2020-07-28	開始されました	JMP Securities	Mkt Outperform
2020-02-24	再開されました	ROTH Capital	Buy
2019-07-19	開始されました	ROTH Capital	Buy
2017-10-09	開始されました	Piper Jaffray	Overweight

すべてを表示

Altimmune Inc (ALT) 最新ニュース

05:27 AM

ALT SEC FilingsAltimmune 10-K, 10-Q, 8-K Forms - Stock Titan

05:27 AM

May 04, 2026

LULU, LCID, ALT stocks hit 52-week lows today: What's driving the selloff? - MSN

May 04, 2026

May 03, 2026

MSN Money - MSN

May 03, 2026

May 02, 2026

Altimmune Stock Dips After $225M Offering Reshapes Funding Outlook - timothysykes.com

May 02, 2026

May 01, 2026

Viking Global (NASDAQ: ALT) reports 6.7% Altimmune stake, 6.7M warrants - Stock Titan

May 01, 2026

Chen Yu and TCG funds report 20M ALT stake (NASDAQ: ALT) - Stock Titan

May 01, 2026

Altimmune (ALT) director Teri Lawver granted 48,800 stock options at $2.82 - Stock Titan

May 01, 2026

Altimmune (ALT) awards 48,800 stock options to director Catherine Sohn - Stock Titan

May 01, 2026

Altimmune (ALT) director receives 48,800-share stock option grant - Stock Titan

May 01, 2026

Altimmune (ALT) director Klaus Schafer awarded 48,800 stock options at $2.82 - Stock Titan

May 01, 2026

[Form 4] Altimmune, Inc. Insider Trading Activity - Stock Titan

May 01, 2026

Altimmune (ALT) director granted 48,800 stock options at $2.82 exercise price - Stock Titan

May 01, 2026

RA Capital, affiliates report 13M shares in Altimmune (ALT) — 6.5% stake - Stock Titan

May 01, 2026

Altimmune (ALT) director receives grant of 48,800 stock options - Stock Titan

May 01, 2026

Dilution fears return: Why ALT stock is getting hit again - MSN

May 01, 2026

ALT Forecast, Price Target & Analyst Ratings | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill

May 01, 2026

Apr 30, 2026

Deep Track reports 9.99% stake in Altimmune (ALT) via warrants and shares - Stock Titan

Apr 30, 2026

ALT Q1'26 Earnings: revenue estimate is 1.11K USD - TradingView

Apr 30, 2026

Altimmune a new buy at Truist on pemvidutide promise - MSN

Apr 30, 2026

Apr 29, 2026

ALT stock drops on wider-than-expected Q4 loss: Retail voices hopes for deal to alleviate cash concerns - MSN

Apr 29, 2026

Altimmune urges earlier clinical action on alcohol use disorder and liver disease link - Traders Union

Apr 29, 2026

Apr 28, 2026

Altimmune catalysts: 2026 data readouts and financing risks - MSN

Apr 28, 2026

Altimmune secures $225 million financing for pemvidutide development - The Pharma Letter

Apr 28, 2026

Apr 27, 2026

Altimmune closes $225M financing for MASH drug trial - Investing.com UK

Apr 27, 2026

Altimmune secures $225M to test GLP-1 in liver disease, eyes first commercial product launch - The Business Journals

Apr 27, 2026

Altimmune Closes $225 Million Oversubscribed Offering to Fund Phase 3 MASH Trial - citybiz

Apr 27, 2026

Altimmune closes $225M financing for MASH drug trial By Investing.com - Investing.com Australia

Apr 27, 2026

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities - The Globe and Mail

Apr 27, 2026

Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock - Insider Monkey

Apr 26, 2026

Altimmune Inc (ALT) 財務データ

収益

当期純利益

現金流量

EPS

ROIV

$28.32

0.14%

RPRX

$50.44

0.48%

BNTX

$95.50

3.88%

INSM

$139.44

0.41%

RVMD

$147.21

0.47%

ONC

$297.49

0.12%

Altimmune Inc (ALT)

Altimmune Inc Stock (ALT) Company Profile

Compare ALT vs VRTX, REGN, ARGX, ALNY, ONC

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Altimmune Inc (ALT) 最新ニュース

ALT SEC FilingsAltimmune 10-K, 10-Q, 8-K Forms - Stock Titan

LULU, LCID, ALT stocks hit 52-week lows today: What's driving the selloff? - MSN

MSN Money - MSN

Altimmune Stock Dips After $225M Offering Reshapes Funding Outlook - timothysykes.com

Viking Global (NASDAQ: ALT) reports 6.7% Altimmune stake, 6.7M warrants - Stock Titan

Chen Yu and TCG funds report 20M ALT stake (NASDAQ: ALT) - Stock Titan

Altimmune (ALT) director Teri Lawver granted 48,800 stock options at $2.82 - Stock Titan

Altimmune (ALT) awards 48,800 stock options to director Catherine Sohn - Stock Titan

Altimmune (ALT) director receives 48,800-share stock option grant - Stock Titan

Altimmune (ALT) director Klaus Schafer awarded 48,800 stock options at $2.82 - Stock Titan

[Form 4] Altimmune, Inc. Insider Trading Activity - Stock Titan

Altimmune (ALT) director granted 48,800 stock options at $2.82 exercise price - Stock Titan

RA Capital, affiliates report 13M shares in Altimmune (ALT) — 6.5% stake - Stock Titan

Altimmune (ALT) director receives grant of 48,800 stock options - Stock Titan

Dilution fears return: Why ALT stock is getting hit again - MSN

ALT Forecast, Price Target & Analyst Ratings | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill

Deep Track reports 9.99% stake in Altimmune (ALT) via warrants and shares - Stock Titan

ALT Q1'26 Earnings: revenue estimate is 1.11K USD - TradingView

Altimmune a new buy at Truist on pemvidutide promise - MSN

ALT stock drops on wider-than-expected Q4 loss: Retail voices hopes for deal to alleviate cash concerns - MSN

Altimmune urges earlier clinical action on alcohol use disorder and liver disease link - Traders Union

Altimmune catalysts: 2026 data readouts and financing risks - MSN

Altimmune secures $225 million financing for pemvidutide development - The Pharma Letter

Altimmune closes $225M financing for MASH drug trial - Investing.com UK

Altimmune secures $225M to test GLP-1 in liver disease, eyes first commercial product launch - The Business Journals

Altimmune Closes $225 Million Oversubscribed Offering to Fund Phase 3 MASH Trial - citybiz

Altimmune closes $225M financing for MASH drug trial By Investing.com - Investing.com Australia

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities - The Globe and Mail

Altimmune raises $225M to fund late-stage MASH drug trial - Stock Titan

Altimmune prices $75M direct offering - MSN

Altimmune shares slide after $75 million registered direct offering - MSN

Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock - Insider Monkey

Altimmune Inc (ALT) 財務データ

収益

当期純利益

現金流量

EPS

ALTに似た銘柄